Adults aged 40 years and older who reported a history of repetitive head impact had more symptoms of depression and difficulties in cognitive functioning, compared with those without such a history, according to a study in Neurology.
Psych Congress cochair Charles Raison, MD, will give a virtual keynote speech August 20, 2020, for the University of Louisville Depression Center’s annual benefit. The event is free and open to the public.
AXS-05, an investigational modulated-delivery tablet combining dextromethorphan and bupropion, significantly improved symptoms of depression in patients with major depressive disorder (MDD) in a recent phase 3 trial, announced developer Axsome Therapeutics Inc.
A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.